APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diagnostic Nuclear Medicines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Diagnostic Nuclear Medicines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025192 pages

Choose your research edition.

Industry ResearchDiagnostic Nuclear Medicines Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Diagnostic Nuclear Medicines Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Diagnostic Nuclear Medicines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diagnostic Nuclear Medicines Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Diagnostic Nuclear Medicines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Diagnostic Nuclear Medicines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Diagnostic Nuclear Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diagnostic Nuclear Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diagnostic Nuclear Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Diagnostic Nuclear Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Diagnostic Nuclear Medicines include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Diagnostic Nuclear Medicines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diagnostic Nuclear Medicines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diagnostic Nuclear Medicines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diagnostic Nuclear Medicines market size, projected growth trends, production technologies, key applications, and end-use industries.

Diagnostic Nuclear Medicines Segment by Company

Bracco Imaging

Cardinal Health

Curium Pharma

GE Healthcare

Jubilant Pharma

Lantheus

SIEMENS

Dongcheng

Eli Lilly

Novartis

China Isotope & Radiation

Diagnostic Nuclear Medicines Segment by Type

Tc-99m

F-18

Other

Diagnostic Nuclear Medicines Segment by Application

Oncology

Cardiology

Other

Diagnostic Nuclear Medicines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Medicines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Diagnostic Nuclear Medicines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Diagnostic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Diagnostic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Diagnostic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Diagnostic Nuclear Medicines Industry Trends Table 2. Diagnostic Nuclear Medicines Industry Drivers Table 3. Diagnostic Nuclear Medicines Industry Opportunities and Challenges Table 4. Diagnostic Nuclear Medicines Industry Restraints Table 5. Global Diagnostic Nuclear Medicines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Diagnostic Nuclear Medicines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Diagnostic Nuclear Medicines Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Diagnostic Nuclear Medicines Sales Market Share by Manufacturers Table 9. Global Diagnostic Nuclear Medicines Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Diagnostic Nuclear Medicines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Diagnostic Nuclear Medicines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Diagnostic Nuclear Medicines Manufacturers, Product Type & Application Table 13. Global Diagnostic Nuclear Medicines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Diagnostic Nuclear Medicines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tc-99m Table 17. Major Manufacturers of F-18 Table 18. Major Manufacturers of Other Table 19. Global Diagnostic Nuclear Medicines Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Diagnostic Nuclear Medicines Sales by Type (2021-2026) & (k units) Table 21. Global Diagnostic Nuclear Medicines Sales by Type (2027-2032) & (k units) Table 22. Global Diagnostic Nuclear Medicines Sales Market Share by Type (2021-2026) Table 23. Global Diagnostic Nuclear Medicines Sales Market Share by Type (2027-2032) Table 24. Global Diagnostic Nuclear Medicines Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Diagnostic Nuclear Medicines Revenue by Type (2021-2026) & (k units) Table 26. Global Diagnostic Nuclear Medicines Revenue by Type (2027-2032) & (k units) Table 27. Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2021-2026) Table 28. Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Oncology Table 30. Major Manufacturers of Cardiology Table 31. Major Manufacturers of Other Table 32. Global Diagnostic Nuclear Medicines Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Diagnostic Nuclear Medicines Sales by Application (2021-2026) & (k units) Table 34. Global Diagnostic Nuclear Medicines Sales by Application (2027-2032) & (k units) Table 35. Global Diagnostic Nuclear Medicines Sales Market Share by Application (2021-2026) Table 36. Global Diagnostic Nuclear Medicines Sales Market Share by Application (2027-2032) Table 37. Global Diagnostic Nuclear Medicines Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Diagnostic Nuclear Medicines Revenue by Application (2021-2026) & (k units) Table 39. Global Diagnostic Nuclear Medicines Revenue by Application (2027-2032) & (k units) Table 40. Global Diagnostic Nuclear Medicines Revenue Market Share by Application (2021-2026) Table 41. Global Diagnostic Nuclear Medicines Revenue Market Share by Application (2027-2032) Table 42. Global Diagnostic Nuclear Medicines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Diagnostic Nuclear Medicines Sales by Region (2021-2026) & (k units) Table 44. Global Diagnostic Nuclear Medicines Sales Market Share by Region (2021-2026) Table 45. Global Diagnostic Nuclear Medicines Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Diagnostic Nuclear Medicines Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Diagnostic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Diagnostic Nuclear Medicines Sales by Country (2021-2026) & (k units) Table 49. North America Diagnostic Nuclear Medicines Sales by Country (2027-2032) & (k units) Table 50. Europe Diagnostic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Diagnostic Nuclear Medicines Sales by Country (2021-2026) & (k units) Table 52. Europe Diagnostic Nuclear Medicines Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Diagnostic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Diagnostic Nuclear Medicines Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Diagnostic Nuclear Medicines Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Diagnostic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Diagnostic Nuclear Medicines Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Diagnostic Nuclear Medicines Sales by Country (2027-2032) & (k units) Table 59. Global Diagnostic Nuclear Medicines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Diagnostic Nuclear Medicines Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Diagnostic Nuclear Medicines Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Diagnostic Nuclear Medicines Revenue Market Share by Region (2021-2026) Table 63. Global Diagnostic Nuclear Medicines Revenue Market Share by Region (2027-2032) Table 64. Bracco Imaging Company Information Table 65. Bracco Imaging Business Overview Table 66. Bracco Imaging Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bracco Imaging Diagnostic Nuclear Medicines Product Portfolio Table 68. Bracco Imaging Recent Development Table 69. Cardinal Health Company Information Table 70. Cardinal Health Business Overview Table 71. Cardinal Health Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Cardinal Health Diagnostic Nuclear Medicines Product Portfolio Table 73. Cardinal Health Recent Development Table 74. Curium Pharma Company Information Table 75. Curium Pharma Business Overview Table 76. Curium Pharma Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Curium Pharma Diagnostic Nuclear Medicines Product Portfolio Table 78. Curium Pharma Recent Development Table 79. GE Healthcare Company Information Table 80. GE Healthcare Business Overview Table 81. GE Healthcare Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. GE Healthcare Diagnostic Nuclear Medicines Product Portfolio Table 83. GE Healthcare Recent Development Table 84. Jubilant Pharma Company Information Table 85. Jubilant Pharma Business Overview Table 86. Jubilant Pharma Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolio Table 88. Jubilant Pharma Recent Development Table 89. Lantheus Company Information Table 90. Lantheus Business Overview Table 91. Lantheus Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Lantheus Diagnostic Nuclear Medicines Product Portfolio Table 93. Lantheus Recent Development Table 94. SIEMENS Company Information Table 95. SIEMENS Business Overview Table 96. SIEMENS Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. SIEMENS Diagnostic Nuclear Medicines Product Portfolio Table 98. SIEMENS Recent Development Table 99. Dongcheng Company Information Table 100. Dongcheng Business Overview Table 101. Dongcheng Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Dongcheng Diagnostic Nuclear Medicines Product Portfolio Table 103. Dongcheng Recent Development Table 104. Eli Lilly Company Information Table 105. Eli Lilly Business Overview Table 106. Eli Lilly Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Eli Lilly Diagnostic Nuclear Medicines Product Portfolio Table 108. Eli Lilly Recent Development Table 109. Novartis Company Information Table 110. Novartis Business Overview Table 111. Novartis Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Novartis Diagnostic Nuclear Medicines Product Portfolio Table 113. Novartis Recent Development Table 114. China Isotope & Radiation Company Information Table 115. China Isotope & Radiation Business Overview Table 116. China Isotope & Radiation Diagnostic Nuclear Medicines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolio Table 118. China Isotope & Radiation Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Diagnostic Nuclear Medicines Distributors List Table 122. Diagnostic Nuclear Medicines Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Diagnostic Nuclear Medicines Product Image Figure 2. Global Diagnostic Nuclear Medicines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diagnostic Nuclear Medicines Market Size (2021-2032) & (US$ Million) Figure 4. Global Diagnostic Nuclear Medicines Sales (2021-2032) & (k units) Figure 5. Global Diagnostic Nuclear Medicines Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Diagnostic Nuclear Medicines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tc-99m Image Figure 9. F-18 Image Figure 10. Other Image Figure 11. Global Diagnostic Nuclear Medicines Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Diagnostic Nuclear Medicines Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Diagnostic Nuclear Medicines Sales Market Share by Type (2021-2032) Figure 14. Global Diagnostic Nuclear Medicines Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Diagnostic Nuclear Medicines Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2021-2032) Figure 17. Oncology Image Figure 18. Cardiology Image Figure 19. Other Image Figure 20. Global Diagnostic Nuclear Medicines Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Diagnostic Nuclear Medicines Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Diagnostic Nuclear Medicines Sales Market Share by Application (2021-2032) Figure 23. Global Diagnostic Nuclear Medicines Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Diagnostic Nuclear Medicines Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Diagnostic Nuclear Medicines Revenue Market Share by Application (2021-2032) Figure 26. North America Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Diagnostic Nuclear Medicines Sales Market Share by Country (2021-2032) Figure 28. U.S. Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Diagnostic Nuclear Medicines Sales Market Share by Country (2021-2032) Figure 33. Germany Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Diagnostic Nuclear Medicines Sales Market Share by Country (2021-2032) Figure 40. China Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Diagnostic Nuclear Medicines Sales Market Share by Country (2021-2032) Figure 48. Brazil Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Diagnostic Nuclear Medicines Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Diagnostic Nuclear Medicines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Diagnostic Nuclear Medicines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Diagnostic Nuclear Medicines Revenue (2021-2032) & (US$ Million) Figure 59. North America Diagnostic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Diagnostic Nuclear Medicines Revenue (2021-2032) & (US$ Million) Figure 61. Europe Diagnostic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Diagnostic Nuclear Medicines Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Diagnostic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Diagnostic Nuclear Medicines Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Diagnostic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Diagnostic Nuclear Medicines Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Diagnostic Nuclear Medicines Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Tc-99m
  • F-18
  • Other
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Bracco Imaging
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus
  • SIEMENS
  • Dongcheng
  • Eli Lilly
  • Novartis
  • China Isotope & Radiation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Diagnostic Nuclear Medicines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Diagnostic Nuclear Medicines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Diagnostic Nuclear Medicines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Diagnostic Nuclear Medicines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Diagnostic Nuclear Medicines Market Dynamics
  1. 2.1 Diagnostic Nuclear Medicines Industry Trends
  2. 2.2 Diagnostic Nuclear Medicines Industry Drivers
  3. 2.3 Diagnostic Nuclear Medicines Industry Opportunities and Challenges
  4. 2.4 Diagnostic Nuclear Medicines Industry Restraints
3 Diagnostic Nuclear Medicines Market by Manufacturers
  1. 3.1 Global Diagnostic Nuclear Medicines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Diagnostic Nuclear Medicines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Diagnostic Nuclear Medicines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Diagnostic Nuclear Medicines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Diagnostic Nuclear Medicines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Diagnostic Nuclear Medicines Manufacturers, Product Type & Application
  7. 3.7 Global Diagnostic Nuclear Medicines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Diagnostic Nuclear Medicines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Diagnostic Nuclear Medicines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Diagnostic Nuclear Medicines Tier 1, Tier 2, and Tier 3
4 Diagnostic Nuclear Medicines Market by Type
  1. 4.1 Diagnostic Nuclear Medicines Type Introduction
  2. 4.1.1 Tc-99m
  3. 4.1.2 F-18
  4. 4.1.3 Other
  5. 4.2 Global Diagnostic Nuclear Medicines Sales by Type
  6. 4.2.1 Global Diagnostic Nuclear Medicines Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Diagnostic Nuclear Medicines Sales by Type (2021-2032)
  8. 4.2.3 Global Diagnostic Nuclear Medicines Sales Market Share by Type (2021-2032)
  9. 4.3 Global Diagnostic Nuclear Medicines Revenue by Type
  10. 4.3.1 Global Diagnostic Nuclear Medicines Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Diagnostic Nuclear Medicines Revenue by Type (2021-2032)
  12. 4.3.3 Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2021-2032)
5 Diagnostic Nuclear Medicines Market by Application
  1. 5.1 Diagnostic Nuclear Medicines Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Cardiology
  4. 5.1.3 Other
  5. 5.2 Global Diagnostic Nuclear Medicines Sales by Application
  6. 5.2.1 Global Diagnostic Nuclear Medicines Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Diagnostic Nuclear Medicines Sales by Application (2021-2032)
  8. 5.2.3 Global Diagnostic Nuclear Medicines Sales Market Share by Application (2021-2032)
  9. 5.3 Global Diagnostic Nuclear Medicines Revenue by Application
  10. 5.3.1 Global Diagnostic Nuclear Medicines Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Diagnostic Nuclear Medicines Revenue by Application (2021-2032)
  12. 5.3.3 Global Diagnostic Nuclear Medicines Revenue Market Share by Application (2021-2032)
6 Global Diagnostic Nuclear Medicines Sales by Region
  1. 6.1 Global Diagnostic Nuclear Medicines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diagnostic Nuclear Medicines Sales by Region (2021-2032)
  3. 6.2.1 Global Diagnostic Nuclear Medicines Sales by Region (2021-2026)
  4. 6.2.2 Global Diagnostic Nuclear Medicines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Diagnostic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Diagnostic Nuclear Medicines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Diagnostic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Diagnostic Nuclear Medicines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Diagnostic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Diagnostic Nuclear Medicines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Diagnostic Nuclear Medicines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Diagnostic Nuclear Medicines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Diagnostic Nuclear Medicines Revenue by Region
  1. 7.1 Global Diagnostic Nuclear Medicines Revenue by Region
  2. 7.1.1 Global Diagnostic Nuclear Medicines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Diagnostic Nuclear Medicines Revenue by Region (2021-2026)
  4. 7.1.3 Global Diagnostic Nuclear Medicines Revenue by Region (2027-2032)
  5. 7.1.4 Global Diagnostic Nuclear Medicines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Diagnostic Nuclear Medicines Revenue (2021-2032)
  8. 7.2.2 North America Diagnostic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Diagnostic Nuclear Medicines Revenue (2021-2032)
  11. 7.3.2 Europe Diagnostic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Diagnostic Nuclear Medicines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Diagnostic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Diagnostic Nuclear Medicines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Diagnostic Nuclear Medicines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bracco Imaging
  2. 8.1.1 Bracco Imaging Company Information
  3. 8.1.2 Bracco Imaging Business Overview
  4. 8.1.3 Bracco Imaging Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bracco Imaging Diagnostic Nuclear Medicines Product Portfolio
  6. 8.1.5 Bracco Imaging Recent Developments
  7. 8.2 Cardinal Health
  8. 8.2.1 Cardinal Health Company Information
  9. 8.2.2 Cardinal Health Business Overview
  10. 8.2.3 Cardinal Health Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cardinal Health Diagnostic Nuclear Medicines Product Portfolio
  12. 8.2.5 Cardinal Health Recent Developments
  13. 8.3 Curium Pharma
  14. 8.3.1 Curium Pharma Company Information
  15. 8.3.2 Curium Pharma Business Overview
  16. 8.3.3 Curium Pharma Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Curium Pharma Diagnostic Nuclear Medicines Product Portfolio
  18. 8.3.5 Curium Pharma Recent Developments
  19. 8.4 GE Healthcare
  20. 8.4.1 GE Healthcare Company Information
  21. 8.4.2 GE Healthcare Business Overview
  22. 8.4.3 GE Healthcare Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GE Healthcare Diagnostic Nuclear Medicines Product Portfolio
  24. 8.4.5 GE Healthcare Recent Developments
  25. 8.5 Jubilant Pharma
  26. 8.5.1 Jubilant Pharma Company Information
  27. 8.5.2 Jubilant Pharma Business Overview
  28. 8.5.3 Jubilant Pharma Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolio
  30. 8.5.5 Jubilant Pharma Recent Developments
  31. 8.6 Lantheus
  32. 8.6.1 Lantheus Company Information
  33. 8.6.2 Lantheus Business Overview
  34. 8.6.3 Lantheus Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lantheus Diagnostic Nuclear Medicines Product Portfolio
  36. 8.6.5 Lantheus Recent Developments
  37. 8.7 SIEMENS
  38. 8.7.1 SIEMENS Company Information
  39. 8.7.2 SIEMENS Business Overview
  40. 8.7.3 SIEMENS Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 SIEMENS Diagnostic Nuclear Medicines Product Portfolio
  42. 8.7.5 SIEMENS Recent Developments
  43. 8.8 Dongcheng
  44. 8.8.1 Dongcheng Company Information
  45. 8.8.2 Dongcheng Business Overview
  46. 8.8.3 Dongcheng Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Dongcheng Diagnostic Nuclear Medicines Product Portfolio
  48. 8.8.5 Dongcheng Recent Developments
  49. 8.9 Eli Lilly
  50. 8.9.1 Eli Lilly Company Information
  51. 8.9.2 Eli Lilly Business Overview
  52. 8.9.3 Eli Lilly Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly Diagnostic Nuclear Medicines Product Portfolio
  54. 8.9.5 Eli Lilly Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Diagnostic Nuclear Medicines Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 China Isotope & Radiation
  62. 8.11.1 China Isotope & Radiation Company Information
  63. 8.11.2 China Isotope & Radiation Business Overview
  64. 8.11.3 China Isotope & Radiation Diagnostic Nuclear Medicines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolio
  66. 8.11.5 China Isotope & Radiation Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Diagnostic Nuclear Medicines Value Chain Analysis
  2. 9.1.1 Diagnostic Nuclear Medicines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Diagnostic Nuclear Medicines Production Mode & Process
  6. 9.2 Diagnostic Nuclear Medicines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Diagnostic Nuclear Medicines Distributors
  9. 9.2.3 Diagnostic Nuclear Medicines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst